Compare Charles River Laboratories Intl. Inc (CRL) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Banco Santander SA — how do they compare? Charles River Laboratories Intl. Inc trades at $302.52 (market cap $14.23B), while Banco Santander SA trades at $13.43 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 13.6× Charles River Laboratories Intl. Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Banco Santander SA for 55 Days on average.
| CRL | SAN | |
|---|---|---|
Market Cap | $14.23B | $192.86B |
Volume | 1,176,885 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $310.77 | $15.05 |
52-Week Low | $149.93 | $9.65 |
Typical Hold Time | 33 Days | 55 Days |
Enterprise Value | $17.06B | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Banco Santander (SAN) trades at $13.66, down 2.5% today, with technical indicators showing bearish momentum. The company reported strong fundamentals with Q2 2026 net income of $14.10 billion and a 26.25% net margin, though cash flow trends show recent operational challenges. Recent developments include the completion of the Webster Financial acquisition, expanding Santander's U.S. presence and diversification.
Outlook remains mixed with analyst consensus at 'Moderate Buy' (64% buy ratings) but technical weakness. Key opportunities include record profitability and strategic acquisitions, while risks involve declining cash flows and high debt levels. The stock's valuation appears reasonable with P/E of 13.55 and P/B of 1.58.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
